Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax

2.2 / 5 stars · 48/110 Roast Me

BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax

BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax of $0 for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.

Discontinued › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax · last filed 2018-10-25

  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2018-06-30 was -$11.00M, a 178.57% decline year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2018-03-31 was -$1.00M, a 109.09% decline year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2017-12-31 was -$6.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2017 was $25.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2016 was -$3.00M, a 115.00% decline from fiscal 2015.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2015 was $20.00M.
  • BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2014 was -$29.00M, a 680.00% decline from fiscal 2013.
Period endOther Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 monthOther Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month as first filedOther Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 6 monthOther Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 monthOther Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 month as first filedOther Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 12 month
2018-09-30$0.00
10-Q · filed 2018-10-25
-$11.00M
derived: sum of 2 quarters · filed 2018-10-25
-$12.00M
10-Q · filed 2018-10-25
-$18.00M
derived: sum of 4 quarters · filed 2018-10-25
2018-06-30-$11.00M
10-Q · filed 2018-07-26
-$12.00M
10-Q · filed 2018-07-26
-$18.00M
derived: sum of 3 quarters · filed 2018-07-26
-$12.00M
derived: sum of 4 quarters · filed 2018-10-25
2018-03-31-$1.00M
10-Q · filed 2018-04-26
-$7.00M
derived: sum of 2 quarters · filed 2018-04-26
-$1.00M
derived: sum of 3 quarters · filed 2018-10-25
$13.00M
derived: sum of 4 quarters · filed 2018-10-25
2017-12-31-$6.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
$0.00
derived: sum of 2 quarters · filed 2018-10-25
$14.00M
derived: sum of 3 quarters · filed 2018-10-25
$25.00M
10-K · filed 2018-02-13
2017-09-30$6.00M
10-Q · filed 2018-10-25
$20.00M
derived: sum of 2 quarters · filed 2018-10-25
$31.00M
10-Q · filed 2018-10-25
-$33.00M
derived: sum of 4 quarters · filed 2018-10-25
2017-06-30$14.00M
10-Q · filed 2018-07-26
$25.00M
10-Q · filed 2018-07-26
-$39.00M
derived: sum of 3 quarters · filed 2018-07-26
-$42.00M
derived: sum of 4 quarters · filed 2018-07-26
2017-03-31$11.00M
10-Q · filed 2018-04-26
-$53.00M
derived: sum of 2 quarters · filed 2018-04-26
-$56.00M
derived: sum of 3 quarters · filed 2018-04-26
-$36.00M
derived: sum of 4 quarters · filed 2018-04-26
2016-12-31-$64.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
-$67.00M
derived: sum of 2 quarters · filed 2018-02-13
-$47.00M
derived: sum of 3 quarters · filed 2018-02-13
-$3.00M
10-K · filed 2018-02-13
2016-09-30-$3.00M
10-Q · filed 2017-10-26
$17.00M
derived: sum of 2 quarters · filed 2017-10-26
$61.00M
10-Q · filed 2017-10-26
$64.00M
derived: sum of 4 quarters · filed 2018-02-13
2016-06-30$20.00M
10-Q · filed 2017-07-27
$64.00M
10-Q · filed 2017-07-27
$67.00M
derived: sum of 3 quarters · filed 2018-02-13
$94.00M
derived: sum of 4 quarters · filed 2018-02-13
2016-03-31$44.00M
10-Q · filed 2017-04-27
$47.00M
derived: sum of 2 quarters · filed 2018-02-13
$74.00M
derived: sum of 3 quarters · filed 2018-02-13
$66.00M
derived: sum of 4 quarters · filed 2018-02-13
2015-12-31$3.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
$30.00M
derived: sum of 2 quarters · filed 2018-02-13
$22.00M
derived: sum of 3 quarters · filed 2018-02-13
$20.00M
10-K · filed 2018-02-13
2015-09-30$27.00M
10-Q · filed 2016-10-27
$19.00M
derived: sum of 2 quarters · filed 2016-10-27
$17.00M
10-Q · filed 2016-10-27
$8.00M
derived: sum of 4 quarters · filed 2017-02-21
2015-06-30-$8.00M
10-Q · filed 2016-07-28
-$10.00M
10-Q · filed 2016-07-28
-$19.00M
derived: sum of 3 quarters · filed 2017-02-21
-$45.00M
derived: sum of 4 quarters · filed 2017-02-21
2015-03-31-$2.00M
10-Q · filed 2016-04-28
-$11.00M
derived: sum of 2 quarters · filed 2017-02-21
-$37.00M
derived: sum of 3 quarters · filed 2017-02-21
-$35.00M
derived: sum of 4 quarters · filed 2017-02-21
2014-12-31-$9.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21
-$35.00M
derived: sum of 2 quarters · filed 2017-02-21
-$33.00M
derived: sum of 3 quarters · filed 2017-02-21
-$29.00M
10-K · filed 2017-02-21
2014-09-30-$26.00M
10-Q · filed 2015-10-27
-$24.00M
derived: sum of 2 quarters · filed 2015-10-27
-$20.00M
10-Q · filed 2015-10-27
-$9.00M
derived: sum of 4 quarters · filed 2016-02-12
2014-06-30$2.00M
10-Q · filed 2015-07-23
$6.00M
10-Q · filed 2015-07-23
$17.00M
derived: sum of 3 quarters · filed 2016-02-12
$28.00M
derived: sum of 4 quarters · filed 2016-02-12
2014-03-31$4.00M
10-Q · filed 2015-04-28
$15.00M
derived: sum of 2 quarters · filed 2016-02-12
$26.00M
derived: sum of 3 quarters · filed 2016-02-12
$27.00M
derived: sum of 4 quarters · filed 2016-02-12
2013-12-31$11.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12
$22.00M
derived: sum of 2 quarters · filed 2016-02-12
$23.00M
derived: sum of 3 quarters · filed 2016-02-12
$5.00M
10-K · filed 2016-02-12
2013-09-30$11.00M
10-Q · filed 2014-10-24
$12.00M
derived: sum of 2 quarters · filed 2014-10-24
-$6.00M
10-Q · filed 2014-10-24
-$10.00M
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30$1.00M
10-Q · filed 2014-07-24
-$17.00M
10-Q · filed 2014-07-24
-$21.00M
derived: sum of 3 quarters · filed 2015-02-13
-$3.00M
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31-$18.00M
10-Q · filed 2014-04-29
-$22.00M
derived: sum of 2 quarters · filed 2015-02-13
-$4.00M
derived: sum of 3 quarters · filed 2015-02-13
-$8.00M
derived: sum of 4 quarters · filed 2015-02-13
2012-12-31-$4.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13
$14.00M
derived: sum of 2 quarters · filed 2015-02-13
$10.00M
derived: sum of 3 quarters · filed 2015-02-13
$3.00M
10-K · filed 2015-02-13
2012-09-30$18.00M
10-Q · filed 2013-10-23
$9.00M
10-Q · filed 2012-10-24
$14.00M
derived: sum of 2 quarters · filed 2013-10-23
$7.00M
10-Q · filed 2013-10-23
-$8.00M
10-Q · filed 2012-10-24
-$20.00M
derived: sum of 4 quarters · filed 2014-02-14
2012-06-30-$4.00M
10-Q · filed 2013-07-25
-$11.00M
10-Q · filed 2013-07-25
-$38.00M
derived: sum of 3 quarters · filed 2014-02-14
-$61.00M
derived: sum of 4 quarters · filed 2014-02-14
2012-03-31-$7.00M
10-Q · filed 2013-04-25
-$34.00M
derived: sum of 2 quarters · filed 2014-02-14
-$57.00M
derived: sum of 3 quarters · filed 2014-02-14
2011-12-31-$27.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14
-$50.00M
derived: sum of 2 quarters · filed 2014-02-14
-$24.00M
10-K · filed 2014-02-14
2011-09-30-$23.00M
10-Q · filed 2012-10-24
$3.00M
10-Q · filed 2012-10-24
2010-12-31$2.00M
10-K · filed 2013-02-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64